Laurent Pierot (Reims, France) talks to BLearning Neuro at ESMINT 2019 (European Society of Minimally Invasive Neurological Therapy; 4–6 September; Nice, France) about the HPC (Hydrophilic Polymer Coating) surface modification technology (phenox) which he says is “very innovative” and could, in the future, “modify our global strategy of treatment for ruptured aneurysms”.
Pierot notes that while flow diversion is a “tremendous revolution” with a very high rate of complete aneurysm occlusion, one major limitation is that patients must be placed under dual antiplatelet therapy (DAPT).
The concept behind the HPC technology is to “mimic naturally what we have in the brain arteries” and will “reduce platelet accumulation inside a device”, Pierot adds. He outlines his own experiences of using the P48 HPC flow diverter and goes on to discuss the preparation of a single arm study, called COATING, which will evaluate both the short and mid-term safety and efficacy of the device.
This video is sponsored by phenox.
